Day One - Wednesday, July 31, 2024

7:45 am Check In & Coffee

8:25 am Chair’s Opening Remarks

Navigating Heart Failure Heterogeneity to Optimize Preclinical Success

8:30 am Exploring Approaches to Address the Heterogeneity of Heart Failure Through Accurate Phenotypes & Pathobiology

  • William Chutkow Executive Director, Heart Failure Drug Discovery, Cardiovascular & Metabolic Diseases, Novartis


  • Assessing the state of play of mechanistic drivers of variability within heart failure 
  • Reviewing the current classification approaches
  • Assessing underlying disease pathologies linked to molecular biological mechanisms of heart failure

9:00 am Optimizing Omic Approaches Within Heart Failure

  • Yuri Kim Advanced Heart Failure & Transplant Cardiologist, Brigham Women's Hospital


  • Exploring omic approaches to from spatial transcriptomics to snRNA-seq to bulk RNAseq for heart failure drug development 
  • Assessing the state of play for heart failure patient profiling through genomics, transcriptomics, proteomics and metabolomics
  • Mapping drivers for heart failure subtypes

9:30 am Speed Networking


A prime chance to make the most of the in-person networking with a niche community of heart failure professionals working in the space. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

10:00 am Morning Break

Spotlighting Developments in Imaging Technologies to Co-Evaluate Preclinical Trial Development

10:45 am Exploring the Potential of Cardiovascular Magnetic Resonance


  • Exploring the capabilities of cardiovascular magnetic resonance for evaluation of patients with heart failure
  • Examining the advantages of cardiovascular magnetic resonance for the assessment of cardiac structure and function 
  • Reviewing the biomarker potential of imaging tools for the assessment of myocardial fibrosis

11:15 am Integrating Advanced Imaging Techniques for Comprehensive Multisystem Insights & Drug Development Enhancement


  • Using advanced MRI and/or PET techniques to complement established methods and further understanding of heart failure 
  • Considering multiple organ effects through imagine
  • Exploring how this add values to heart failure drug development

Streamlining Human Centric iPSCs & In Vivo Preclinical Models

11:45 am Panel Discussion: Exploring Developments Within Modelling to Access the Suitability of Different Approaches


  • How can models be manipulated to maximise translatability?
  • How can the back translation from patient phenotypes be maximized?
  • How can human based research be prioritized through human bio samples and integrating human data? 

12:15 pm Advancing Cardiovascular Drug Development Through Precise Models


  • Utilizing gold standard animal models
  • Optimizing treatment of cardiovascular diseases and cardiometabolic complications
  • Delving into functional exploration and pharmacological characterization using ex-vivo and in vitro assays

12:30 pm Lunch & Networking

2:00 pm Optimizing HFpEF Mouse Model Development Through AAV-Renin to Increase Translatability


  • Enhancing translational value of preclinical HFpEF model 
  • Utility of heart rate variability and chronic incompetence as a translationally relevant prognostic markers of heart failure in preclinical model

2:30 pm Roundtable Discussion | Optimal Mechanisms for Combatting Heart Failure Heterogeneity


A more practical and highly interactive breakout roundtable session where attendees can crowd-source solutions and share opinions on pre-assigned topic areas:

Optimal Phenotyping

What strategies can we employ to overcome the broad heart failure categorization? What characterisation approaches are most fruitful? Should differentiation be clinical, metabolic or genetic?

Back Translation

How can the back translation of large data from clinical trials with ACE inhibitors, SGLT2 inhibitors, beta blockers and GLP-1 analogs be effectively utilised to drive innovation and progression for heart failure target identification and biomarker development? 

Moderators and Audience Debate Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.

Exploring the Potential of AI for HF Target Identification

3:45 pm Capitalizing on AI to Improve Ingenuity Pathways Analysis & Unlock Efficient Heart Failure Drug Screening

  • Joseph Wu Director Stanford Cardiovascular Institute & Professor, Stanford Genome Technology Center


  • Translating heart failure clinical trials into a dish
  • Utilizing stem cell genetics and machine learning for docking analysis of heart failure drug targets
  • Commutating three-dimensional structures for heart failure drug targets using machine learning

4:15 pm Leveraging Machine Learning in Target Discovery & Validation for Precision Cardiology


  • Outlining our experience in external collaborations using machine learning methods on single-cell transcriptomics and cardiac magnetic resonance imaging
  • Detailing how this has fueled our aspiration to build a robust internal platform to integrate high-throughput phenomic data 
  • Utilizing machine learning to drive disease understanding and uncover novel drug targets

4:20 pm Chair’s Closing Remarks

4:25 pm Scientific Poster Session


Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversions and relationship building. Explore a range of exciting poster presentations of the latest heart failure strategies and showcase your own innovations in heart failure drug development. Don’t miss out on the chance to connect, learn, and present.

5:00 pm End of Day One

Day One - Wednesday, July 31, 2024